Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
Immunohistochemistry (IHC) Quality Control
Re-validating borderline ER, PR, HER2, PD-L1 (22C3/SP263), and MMR proteins with standardized automated staining.
Histologic Grading & Differentiation
Standardizing Nottingham (breast), Gleason (prostate), and FIGO (gynecologic) grading to prevent undertreatment or overtreatment.
Surgical Margin Clearance Verification
Confirming true negative margins vs microscopic positive ink on tumor on complex partial organ resection specimens.
Lymphovascular & Perineural Invasion (LVI / PNI)
Critical prognostic markers indicating micro-metastatic risk that dictate whether adjuvant systemic therapy is warranted.
Tumor Subtyping & Lineage Determination
Resolving poorly differentiated carcinoma vs lymphoma vs melanoma vs sarcoma with specialized antibody cocktails.
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
Benign vs Malignant Confirmation
Preventing traumatic unnecessary surgeries or toxic chemotherapy for benign mimickers (e.g., sclerosing adenosis, reactive lymphadenopathy).
Invasive vs In Situ Disease Distinction
Ensuring DCIS or non-invasive papillary lesions are not undertreated if focal invasive components were missed on initial cuts.
Discordant Biomarker Reconciliation
Resolving disparate results between a needle biopsy and final surgical excision specimen.
Tissue Sufficiency for Molecular NGS
Assessing tumor purity and cellularity to guarantee sufficient neoplastic content for successful Next-Generation Sequencing.
Records Required for Pathology Review Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Pathology Review
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Radiology Second Opinion
Radiology reports are often produced under high-volume general hospital conditions where subtle oncologic nuances can be overlooked. Up to 20% of expert radiology second opinions identify critical discrepancies: unrecognized liver or peritoneal metastases, missed vascular encasement that alters surgical resectability, or confusion between treatment-induced pseudo-progression and true tumor growth.
Breast Cancer Second Opinion
Breast cancer care has evolved from one-size-fits-all chemotherapy to biomarker-driven, subtype-specific regimens. Second opinions frequently alter therapy by re-evaluating borderline HER2-low vs HER2-zero immunohistochemistry (IHC 1+ or IHC 2+/FISH negative), verifying ER/PR expression cutoffs, interpreting ambiguous Oncotype DX or MammaPrint genomic recurrence scores, and assessing surgical lumpectomy margins.
Lung Cancer Second Opinion
Advanced Non-Small Cell Lung Cancer (NSCLC) management hinges completely on comprehensive genomic profiling. Patients frequently start standard chemotherapy and immunotherapy before complete NGS results return, which can cause severe toxicities if an unspotted EGFR or ALK driver is present. A specialized lung second opinion verifies NGS adequacy, evaluates liquid vs tissue biopsy discordance, and refines PET-CT / EBUS mediastinal nodal staging.
Prostate Cancer Second Opinion
Prostate cancer is characterized by widespread overtreatment of indolent tumors and undertreatment of aggressive variants. Central pathology re-evaluation modifies the assigned Gleason score or ISUP Grade Group in up to 25% of cases. A second opinion integrates multiparametric MRI (PI-RADS v2.1), Decipher / Prolaris genomic testing, and PSMA PET-CT to determine whether active surveillance, robotic prostatectomy, focal therapy, or SBRT is the optimal pathway.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Pathology Review Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.